Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Approval for BL-M14D1 Clinical Trial in Solid Tumors

Fineline Cube Jul 12, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

Beijing Sun-Novo Gets NMPA Green Light for STC008 Clinical Trial in Tumor Cachexia

Fineline Cube Jul 12, 2024

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a biopharmaceutical company based in China, has...

Company Medical Device

Haohai Biotech’s Sodium Hyaluronate Gel Receives NMPA Approval for Aesthetic Treatments

Fineline Cube Jul 12, 2024

Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366) has announced that it has...

Company

Danaher Corporation Launches Western Innovation Center in Chongqing

Fineline Cube Jul 12, 2024

Danaher Corporation (NYSE: DHR), a leading science and technology services provider based in the U.S.,...

Company Deals

Salus Biotech Partners with Xi’an Jiaotong University for Single-Cell Omics Innovation

Fineline Cube Jul 12, 2024

Salus Biotech, a Shenzhen-based biotechnology company, has entered into a strategic partnership with the Single-cell...

Company Drug

KeChow Pharma’s Keluping, First NRAS Mutant Melanoma Therapy, Hits the Market

Fineline Cube Jul 12, 2024

Shanghai-based KeChow Pharma has announced the official market launch of its groundbreaking drug, Keluping (tunlametinib),...

Company Deals

Biokin Pharmaceutical Co., Ltd Eyes Secondary Listing on HKEX, Co-Sponsored by Goldman Sachs and Others

Fineline Cube Jul 11, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a company listed on the Shanghai Stock Exchange’s...

Company Deals

Allist Pharmaceuticals Faces Arbitration Over Promotion Agreement for Furmonertinib

Fineline Cube Jul 11, 2024

Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received a...

Company

Bayer Restructures China Business into Five Sectors and Six Departments

Fineline Cube Jul 11, 2024

Bayer (ETR: BAYN), the German pharmaceutical and life sciences giant, has announced a strategic restructuring...

Company Deals Digital

Digital Health China Partners with Huawei to Launch Intelligent Multimodal Big Data System for Healthcare

Fineline Cube Jul 11, 2024

Digital Health China Technologies Co., Ltd., a leading cloud-based healthcare service provider based in China,...

Company

Pfizer and AbbVie Announce Leadership Changes in Global R&D Divisions

Fineline Cube Jul 11, 2024

In significant executive reshuffling, Pfizer Inc. (NYSE: PFE) and AbbVie (NYSE: ABBV) have both announced...

Company Deals

Pfizer Collaborates with Evotec for Drug Candidates in Metabolic and Infectious Diseases

Fineline Cube Jul 11, 2024

Pfizer Inc. (NYSE: PFE) has entered into a multi-year collaboration with Germany-based biotechnology company Evotec...

Company Deals

Novo Nordisk Partners with Indonesia’s Bio Farma to Boost Asia-Pacific Diabetes Drug Production

Fineline Cube Jul 11, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is...

Company

Abbisko Therapeutics Forecasts Profits and Revenue Boost in H1 2024 on Merck Deal

Fineline Cube Jul 11, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has released a positive financial...

Company

Junshi Biosciences’ Subsidiary Secures EU GMP Certification, Strengthening Loqtorzi’s Market Prospects

Fineline Cube Jul 11, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company Deals

AFT Pharmaceuticals Partners with Hainan Haiyao for Distribution of Crystaderm Cream in China

Fineline Cube Jul 10, 2024

AFT Pharmaceuticals (JSE: AFT, ASX: ASX), a company based in New Zealand, has announced an...

Company Drug

Amgen Halts Development of Claudin 6-Targeting BiTE Immune Therapy AMG 794

Fineline Cube Jul 10, 2024

Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has decided to...

Company Drug

Kymera Therapeutics’ Stock Soars on Sanofi’s Plans to Expand KT-474 Clinical Trials

Fineline Cube Jul 10, 2024

Kymera Therapeutics Inc. (NASDAQ: KYMR), a biopharmaceutical company based in the U.S., has announced that...

Company Deals

BGI Genomics’ Subsidiary Inks 3-Year Noninvasive Prenatal Test Agreement with Heilongjiang Province

Fineline Cube Jul 10, 2024

BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced...

Company Drug

Shanghai Vitalgen BioPharma Launches Phase I/II Gene Therapy Trial for Parkinson’s Disease

Fineline Cube Jul 10, 2024

Shanghai Vitalgen BioPharma Co., Ltd, a biopharmaceutical company based in China, has initiated a Phase...

Posts pagination

1 … 339 340 341 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.